Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.68 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462972 | 1.00 | NPC1 (0.73) | NPC1RAB9AADORA3ADORA2AADORA2B | |
| SCHEMBL4255341 | 0.88 | NPC1 (0.81) | NPC1RAB9AADORA3ADORA2AADORA2B | |
| SCHEMBL12228168 | 0.88 | RAB9A (0.71) | NPC1RAB9AKCNK3KCNK9SMN1; SMN2 | |
| SCHEMBL28816526 | 0.87 | KCNK3 (0.73) | NPC1RAB9AADORA3ADORA2AADORA2B | |
| SCHEMBL19472705 | 0.87 | MAPT (0.62) | NPC1RAB9AADORA3ADORA2AADORA2B | |
| SCHEMBL4247170 | 0.86 | KCNK3 (0.91) | NPC1RAB9AKCNK3KCNK9MEN1 | |
| SCHEMBL29768474 | 0.85 | NPC1 (0.76) | NPC1RAB9AADORA3ADORA2AADORA2B | |
| SCHEMBL28579555 | 0.85 | NPC1 (0.76) | NPC1RAB9AADORA3ADORA2AADORA2B | |
| SCHEMBL259706 | 0.85 | MEN1 (0.77) | NPC1RAB9AKCNK3KCNK9SMN1; SMN2 | |
| SCHEMBL3794687 | 0.85 | NPC1 (1.00) | NPC1RAB9AADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115925574-B | Diamine monomer and polyimide film containing large-volume twisted structure and preparation method thereof | 安徽国风新材料股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-115925574-A | Diamine monomer containing large-volume twisted structure, polyimide film and preparation method of polyimide film | 安徽国风新材料股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115925574-B | Diamine monomer and polyimide film containing large-volume twisted structure and preparation method thereof | 安徽国风新材料股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-115925574-A | Diamine monomer containing large-volume twisted structure, polyimide film and preparation method of polyimide film | 安徽国风新材料股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | NPC1 869/4885RAB9A 733/4885ADORA3 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.